Aldosterone: Evidence-Based Ways to Improve Your Levels

What Aldosterone Does in the Body

Aldosterone is the primary mineralocorticoid hormone produced by the zona glomerulosa of the adrenal cortex. It acts on the distal nephron and collecting duct of the kidney, telling epithelial cells to reabsorb sodium and excrete potassium through epithelial sodium channels (ENaC). This single hormone exerts outsized control over blood pressure, plasma volume, and electrolyte balance.

The renin-angiotensin-aldosterone system (RAAS) governs aldosterone secretion. When blood pressure drops or sodium delivery to the macula densa falls, the kidneys release renin, which converts angiotensinogen to angiotensin I. Angiotensin-converting enzyme (ACE) then produces angiotensin II, which stimulates the adrenal glands to secrete aldosterone 1. Potassium also directly stimulates aldosterone release. A rise in serum potassium of just 0.1 mEq/L can measurably increase aldosterone output, making the hormone a frontline defense against hyperkalemia 2.

ACTH from the pituitary plays a minor modulatory role, which is why aldosterone shows a mild diurnal rhythm similar to cortisol but is not primarily ACTH-dependent.

Normal Aldosterone Ranges and How to Interpret Them

Reference values depend on posture, sodium intake, and assay method. Most laboratories report an upright (standing) morning aldosterone of 1 to 16 ng/dL, while supine values typically fall between 1 and 7 ng/dL. The aldosterone-to-renin ratio (ARR) is the primary screening metric for autonomous aldosterone production. An ARR above 30 ng/dL per ng/mL/h, paired with an aldosterone level exceeding 10-15 ng/dL, warrants confirmatory testing according to the 2016 Endocrine Society Clinical Practice Guideline 3.

Context matters. Sodium intake suppresses aldosterone, so a high-salt diet can mask primary aldosteronism. Conversely, a very low-sodium diet or dehydration raises aldosterone physiologically. Pregnancy raises aldosterone two- to eight-fold by the third trimester, and this is normal 4. Medications including ACE inhibitors, ARBs, spironolactone, and certain diuretics alter the ARR and must be washed out before screening. The Endocrine Society recommends a minimum four-week washout for spironolactone and a two-week washout for beta-blockers before testing 3.

What High Aldosterone Means: Primary Aldosteronism

Primary aldosteronism (PA), historically called Conn syndrome, occurs when one or both adrenal glands produce excess aldosterone independent of the renin-angiotensin axis. It is not rare. A 2020 cross-sectional analysis of over 1,000 normotensive and hypertensive subjects found biochemical evidence of PA in 11.3% of those with hypertension and in 5.9% of normotensive individuals, suggesting the condition is widely underdiagnosed 5.

The clinical consequences extend beyond blood pressure. Patients with PA face higher rates of atrial fibrillation, heart failure, stroke, and chronic kidney disease compared to patients with essential hypertension matched for blood pressure levels 6. A 2018 meta-analysis reported that PA patients had a 2.05-fold increased odds of atrial fibrillation and a 1.77-fold increased odds of heart failure relative to essential hypertension controls 6.

The two most common subtypes are aldosterone-producing adenoma (APA), a benign tumor in one adrenal gland, and bilateral adrenal hyperplasia (BAH). APA accounts for roughly 30-40% of PA cases and is potentially curable with surgery. BAH makes up 60-70% and requires lifelong medical management 3.

Evidence-Based Strategies to Lower Aldosterone

Reducing pathologically elevated aldosterone requires identifying the subtype first. The Endocrine Society recommends adrenal CT followed by adrenal vein sampling (AVS) in surgical candidates to distinguish unilateral from bilateral disease 3.

Surgical Intervention for Unilateral Disease

Laparoscopic adrenalectomy is the treatment of choice for APA. A systematic review of 32 studies encompassing over 2,100 patients found that unilateral adrenalectomy produced complete biochemical cure in 94-100% of cases, while complete clinical cure (resolution of hypertension without medication) occurred in 37-68% 7. Younger age, shorter duration of hypertension, and fewer antihypertensive medications at baseline predicted better blood pressure outcomes. The Primary Aldosteronism Surgical Outcome (PASO) study established standardized criteria for defining surgical success: complete clinical success requires normotension without antihypertensives at 6-12 months 7.

Mineralocorticoid Receptor Antagonists

For bilateral disease or patients who decline surgery, spironolactone is the first-line pharmacologic agent. Typical starting doses range from 12.5 to 25 mg daily, titrated up to 100 mg daily based on blood pressure and potassium response. The drug blocks aldosterone at its receptor in the kidney, heart, and vasculature.

Spironolactone carries antiandrogenic side effects. Gynecomastia, breast tenderness, and erectile dysfunction occur in 6-10% of men at doses above 50 mg daily 8. Eplerenone, a selective mineralocorticoid receptor antagonist, avoids these effects but requires twice-daily dosing and is generally less potent milligram-for-milligram. The EPHESUS trial demonstrated eplerenone's cardiovascular benefit in heart failure patients, reducing all-cause mortality by 15% (RR 0.85 to 95% CI 0.75-0.96) 9.

Dr. William F. Young Jr. of the Mayo Clinic has stated: "For patients with bilateral adrenal hyperplasia, spironolactone remains the cornerstone of therapy. The goal is to normalize potassium and achieve the lowest tolerable blood pressure with the fewest medications" 3.

Dietary Sodium Restriction

Sodium restriction amplifies the effectiveness of mineralocorticoid receptor antagonists. The DASH-Sodium trial showed that reducing sodium intake from 3 to 300 mg to 1 to 500 mg daily lowered systolic blood pressure by an average of 7.1 mmHg in hypertensive participants 10. In PA patients specifically, excess sodium accelerates target organ damage because aldosterone-driven sodium reabsorption is already running unchecked. The Endocrine Society guideline recommends sodium intake below 2 to 300 mg per day for all PA patients, with individualized targets as low as 1 to 500 mg daily when tolerated 3.

Potassium Optimization

Hypokalemia is a hallmark of PA, though it is absent in up to 50% of cases at diagnosis. Correcting potassium to 3.5-5.0 mEq/L is a parallel priority. Oral potassium chloride supplementation (40-120 mEq daily in divided doses) is often needed while the MRA is titrated. Dietary potassium from foods such as potatoes, bananas, spinach, and beans supports but rarely replaces supplementation in moderate-to-severe PA 3.

What Low Aldosterone Means: Hypoaldosteronism

Low aldosterone production is less common but clinically significant. It presents with hyperkalemia, mild metabolic acidosis (type 4 renal tubular acidosis), and sometimes orthostatic hypotension. Salt craving is a frequent patient-reported symptom.

The most common cause is hyporeninemic hypoaldosteronism, which occurs in 5-10% of patients with diabetic nephropathy 11. Damaged juxtaglomerular cells produce insufficient renin, leading to low angiotensin II and consequently low aldosterone. NSAIDs, calcineurin inhibitors (tacrolimus, cyclosporine), heparin, and trimethoprim also suppress aldosterone through distinct mechanisms 11.

Primary adrenal insufficiency (Addison disease) causes combined cortisol and aldosterone deficiency. The Endocrine Society's 2016 guideline on adrenal insufficiency recommends fludrocortisone replacement at 0.05 to 0.2 mg daily, titrated to maintain plasma renin activity in the upper-normal range and serum potassium between 3.5 and 5.0 mEq/L 12.

Evidence-Based Strategies to Raise Aldosterone

Addressing low aldosterone depends on the underlying cause.

Fludrocortisone Replacement

Fludrocortisone (Florinef) is a synthetic mineralocorticoid that mimics aldosterone at the renal tubule. Standard dosing begins at 0.05 mg daily, with adjustments every one to two weeks based on standing blood pressure, serum potassium, and plasma renin activity. Most patients stabilize at 0.1 mg daily. The 2016 Endocrine Society guideline for adrenal insufficiency states: "Mineralocorticoid replacement with fludrocortisone is recommended for all patients with primary adrenal insufficiency. Dose adjustment should be guided by clinical assessment (salt craving, postural hypotension) and serum electrolytes" 12.

Patients on fludrocortisone need regular monitoring. Excessive doses cause hypertension, hypokalemia, and edema. Sitting and standing blood pressure checks, along with serum sodium and potassium levels, should be assessed at baseline, at each dose change, and every three to six months once stable 12.

Sodium Loading and Hydration

For mild hypoaldosteronism without severe hyperkalemia, increasing dietary sodium to 3,000-5 to 000 mg daily may be sufficient to maintain intravascular volume and blood pressure without pharmacologic intervention. This approach is particularly useful in hyporeninemic hypoaldosteronism where the potassium elevation is modest (5.0-5.5 mEq/L) 11.

Removing Offending Medications

Drug-induced hypoaldosteronism often reverses when the causative agent is discontinued or substituted. NSAIDs suppress renin release. Heparin directly inhibits aldosterone synthase. A 2004 review found that unfractionated heparin reduced aldosterone by 30-50% within 72 hours of initiation, while low-molecular-weight heparins had a smaller effect 11. Medication review is the simplest and most effective intervention when drug-induced suppression is suspected.

Lifestyle Factors That Influence Aldosterone

Several modifiable behaviors affect RAAS activity, though none replace medical therapy in confirmed aldosteronism.

Exercise acutely raises aldosterone during activity due to sympathetic activation and volume shifts, but regular aerobic training reduces resting aldosterone over weeks to months. A 2014 study of 50 sedentary hypertensive adults found that 12 weeks of moderate aerobic exercise (150 minutes per week) reduced plasma aldosterone by 18% compared to controls 13.

Sleep and circadian rhythm modulate the RAAS. Aldosterone secretion follows a diurnal pattern, peaking in the early morning hours. Obstructive sleep apnea (OSA) is independently associated with elevated aldosterone. A prospective study of 109 treatment-resistant hypertensive patients found that 34% met criteria for PA, and severity of OSA correlated with aldosterone levels 14. Treatment of OSA with CPAP reduced aldosterone by an average of 1.7 ng/dL over 6 months in a subset of these patients.

Stress activates the RAAS via sympathetic nervous system stimulation. Chronic psychological stress raises circulating angiotensin II and aldosterone, contributing to salt-sensitive hypertension. While stress reduction techniques have not been tested specifically in PA populations, the AHA recognizes that chronic stress contributes to sustained hypertension 15.

Body weight matters. Adipose tissue produces angiotensinogen, the RAAS precursor. Obesity is associated with elevated aldosterone independent of renal perfusion. Weight loss of 5-10% body weight has been shown to reduce plasma aldosterone concentration by 20-30% in obese hypertensive patients 16.

Monitoring and Follow-Up

Regardless of direction (high or low), aldosterone management requires structured monitoring. For PA patients on spironolactone or eplerenone, check serum potassium and creatinine at 1 week, 4 weeks, and then every 3 months for the first year. Blood pressure targets should follow ACC/AHA guidelines: below 130/80 mmHg for most adults with hypertension 17.

For post-adrenalectomy PA patients, repeat ARR testing at 3 months confirms biochemical cure. Persistent hypertension despite normalized aldosterone may reflect remodeled vasculature or coexisting essential hypertension, which affects up to 40% of post-surgical PA patients.

For patients on fludrocortisone, annual reassessment of the replacement dose prevents overtreatment. Serum sodium above 145 mEq/L, ankle edema, or new hypertension suggests the dose is too high and should be reduced by 0.05 mg increments 12.

The Endocrine Society recommends lifelong follow-up for all PA patients, including those with surgical cures, because cardiovascular risk remains elevated for years after treatment initiation 3.